Beginning January 1, 2019, Anthem Blue Cross (Anthem) Federal Employee Program® (FEP) benefit procedures will change for the autoimmune infusion drug infliximab (brand names Remicade, Inflectra, and Renflexis). Members currently receiving the drug may be covered under either pharmacy or medical benefits. Howeber, members who receive a first infusion or or after January 1, 2019, can only receive the drug under medical benefits. Members who receive it under pharmacy benefits prior to January 1, 2019, will continue receiving it under pharmacy benefits.

 

If you have anu questions please contact FEP Customer Serivce at: 1-800-284-9093.

 



Featured In:
December 2018 Anthem Blue Cross Provider Newsletter - California